Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile.

IF 1 Q4 ONCOLOGY Melanoma Management Pub Date : 2020-07-16 DOI:10.2217/mmt-2020-0002

Alexandra Ikeguchi, Michael Machiorlatti, Sara K Vesely

引用次数: 7

Abstract

Background: Randomized comparisons have demonstrated survival benefit of adjuvant immunotherapy in node-positive melanoma patients but have limited power to determine if this benefit persists across various demographic factors.

Materials & methods: We assessed the impact of demographic factors on the survival benefit of adjuvant immunotherapy in a database of 38,189 node-positive melanoma patients using the Kaplan-Meier method and Cox proportional hazards models.

Results: All assessed demographic factors other than race significantly impacted survival of node-positive melanoma patients in univariate analysis. In multivariable analysis, only the age group interacted with immunotherapy.

Conclusion: Analysis of this large database of unselected node-positive melanoma patients demonstrated a positive survival benefit of immunotherapy across all demographic factors assessed and the impact was greater for patients 65 years of age and older.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

黑色素瘤辅助免疫治疗结果的人口统计学差异。

背景:随机比较已经证明了辅助免疫治疗对淋巴结阳性黑色素瘤患者的生存益处，但确定这种益处是否在各种人口因素中持续存在的能力有限。材料与方法:我们使用Kaplan-Meier法和Cox比例风险模型评估了人口统计学因素对38189例淋巴结阳性黑色素瘤患者辅助免疫治疗生存获益的影响。结果:在单变量分析中，除种族外，所有评估的人口统计学因素显著影响淋巴结阳性黑色素瘤患者的生存。在多变量分析中，只有年龄组与免疫治疗相互作用。结论:对未选择淋巴结阳性黑色素瘤患者的大型数据库的分析表明，免疫治疗在所有评估的人口统计学因素中都有积极的生存益处，对65岁及以上患者的影响更大。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.